Antisense Therapeutics Limited (ATHJF)
USD 0.01
(-76.0%)
USD 0.01
(-76.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 2.96 Million | 1.57 Million | 1.77 Million | 577.76 Thousand | 668.43 Thousand | 586.78 Thousand |
| Cost of Revenue | 62.14 Thousand | 95.19 Thousand | 89.21 Thousand | 103.31 Thousand | 107.6 Thousand | 5377.00 |
| Gross Profit | 2.9 Million | 1.48 Million | 1.68 Million | 474.44 Thousand | 560.83 Thousand | 581.41 Thousand |
| Operating Expenses | 14.73 Million | 13.34 Million | 7.61 Million | 8.68 Million | 6.66 Million | 3.57 Million |
| Selling, General and Administrative Expenses | 4.03 Million | 3.05 Million | 2.92 Million | 3.55 Million | 4.45 Million | 1.81 Million |
| Research and Development Expenses | 10.69 Million | 10.16 Million | 4.53 Million | 4.91 Million | 1.89 Million | 1.76 Million |
| Other Expenses | - | 1.58 Million | 1.77 Million | 629.19 Thousand | 740.09 Thousand | - |
| Cost and Expenses | 14.8 Million | 13.34 Million | 7.61 Million | 8.68 Million | 6.66 Million | 3.58 Million |
| Operating Income | -11.83 Million | -13.34 Million | -7.61 Million | -8.68 Million | -6.66 Million | -3.58 Million |
| Interest Expense | 3603.00 | 8154.00 | 11.9 Thousand | 10.73 Thousand | 12.53 Thousand | - |
| Income Tax Expense | -2.35 Million | -376.76 Thousand | -22.27 Thousand | 6553.00 | -17.99 Thousand | -576.69 Thousand |
| Earnings before Tax | -11.91 Million | -11.37 Million | -5.81 Million | -8.06 Million | -5.9 Million | -3.52 Million |
| Net Income | -11.91 Million | -11.37 Million | -5.81 Million | -8.06 Million | -5.9 Million | -2.94 Million |
| Earnings Per Share Basic | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Earnings Per Share Diluted | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted Average Shares Outstanding | 881.2 Million | 668.85 Million | 631.78 Million | 540.98 Million | 454.51 Million | 386.11 Million |
| Weighted Average Shares Outstanding (Diluted) | 881.14 Million | 668.84 Million | 634.29 Million | 540.98 Million | 455.83 Million | 386.09 Million |
| Gross Margin | 0.98 | 0.94 | 0.95 | 0.82 | 0.84 | 0.99 |
| EBIT Margin | -4.01 | -8.39 | -4.23 | -14.85 | -9.81 | -6.10 |
| Profit Margin | -4.02 | -7.20 | -3.27 | -13.95 | -8.84 | -5.02 |
| EBITDA | -11.9 Million | -11.36 Million | -5.82 Million | -8.1 Million | -5.99 Million | -3.57 Million |
| Earnings Before Tax Margin | -3.99 | -8.45 | -4.28 | -15.03 | -9.97 | -6.11 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | - | 884.03 Thousand | 884.03 Thousand | 600.05 Thousand | 600.05 Thousand | 1.57 Million |
| Cost of Revenue | 79.42 Thousand | 9506.00 | 9506.00 | 47.4 Thousand | 21.56 Thousand | 95.19 Thousand |
| Gross Profit | -79.42 Thousand | 874.52 Thousand | 874.52 Thousand | 552.64 Thousand | 578.48 Thousand | 1.48 Million |
| Operating Expenses | 14.8 Million | 4.44 Million | 4.44 Million | 5.89 Million | 2.94 Million | 13.34 Million |
| Selling, General and Administrative Expenses | - | 1.14 Million | 1.14 Million | 1.78 Million | 869.61 Thousand | - |
| Research and Development Expenses | - | 3.29 Million | 3.29 Million | 4.1 Million | 2.05 Million | - |
| Other Expenses | - | - | - | - | - | 1.58 Million |
| Cost and Expenses | 14.88 Million | 4.45 Million | 4.45 Million | 5.93 Million | 2.97 Million | 13.34 Million |
| Operating Income | -14.88 Million | -3.57 Million | -3.57 Million | -5.93 Million | -2.36 Million | -13.34 Million |
| Interest Expense | 3603.00 | 985.00 | - | 2618.00 | - | 8154.00 |
| Income Tax Expense | -2.35 Million | -1.56 Million | -16 Thousand | -789.13 Thousand | - | -376.76 Thousand |
| Earnings before Tax | -14.27 Million | -3.58 Million | -3.58 Million | -5.53 Million | -2.37 Million | -11.37 Million |
| Net Income | -11.91 Million | -3.58 Million | -3.58 Million | -4.74 Million | -2.37 Million | -11.37 Million |
| Earnings Per Share Basic | - | -0.00 | -0.00 | -0.01 | -0.00 | - |
| Earnings Per Share Diluted | - | -0.00 | -0.00 | -0.01 | -0.00 | - |
| Weighted Average Shares Outstanding | 881.14 Million | 1.03 Billion | 1.03 Billion | 724.11 Million | 718.68 Million | 669.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 881.14 Million | 1.03 Billion | 1.03 Billion | 724.11 Million | 724.11 Million | 669.02 Million |
| Gross Margin | - | 0.99 | 0.99 | 0.92 | 0.96 | 0.94 |
| EBIT Margin | - | -4.05 | -4.05 | -9.82 | -3.94 | - |
| Profit Margin | - | -4.06 | -4.06 | -7.90 | -3.95 | -7.20 |
| EBITDA | - | -3.58 Million | -3.58 Million | -5.89 Million | -2.36 Million | - |
| Earnings Before Tax Margin | - | -4.04 | -4.04 | -9.90 | -3.95 | -8.45 |
WLDS
JIN
0258
OPRX
APE
NVCR